Company / R&D Expense
Travere Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$206.0M
FY2025
5-year range
$7.5M / $245.0M
FY2021-FY2025
Trend
-5.3%
vs FY2024
Sector context
#81 of 210
Health Care
What the data says
At $206M, Travere Therapeutics, Inc.'s r&d expense ranks #81 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $8M in FY2022 to $245M in FY2023.
Based on SEC 10-K filings.
$206M in FY2025 with a 5-year CAGR of +10.7%.
Declined from $245M to $206M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +201.7%
- 5-Year CAGR
- +10.7%
- 10-Year CAGR
- -
Sector benchmark
#81 of 210 in Health CareTop 39% of 210This company $206.0M Sector average $644.1M
▼
-68.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.7%, indicating consistent growth.
- In FY2025, r&d expense decreased 5.3% year-over-year.
- Ranks #81 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $206.0M | -5.3% |
| FY2024 | $217.5M | -11.2% |
| FY2023 | $245.0M | +3166.5% |
| FY2022 | $7.5M | -94.7% |
| FY2021 | $141.0M | +13.9% |
| FY2020 | $123.8M | +58.3% |
| FY2019 | $78.2M | +10.4% |
| FY2018 | $70.8M | +40.4% |
| FY2017 | $50.4M | +5.5% |
| FY2016 | $47.8M | -5.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026